Leveraging Technology to Cut Through the REMS Confusion
The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.
You may also like:
With an increasing number of diabetes patients needing care, and not enough healthcare professionals to adequately manage their chronic conditions, community pharmacists may be uniquely positioned to help fill these needs. ...
As I write this blog, I am wrapping up participating in the annual meeting of one of my favorite organizations: The American Society of Automation in Pharmacy (ASAP). ...
This is the last week for the public to submit comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!